[link removed]
[link removed] [link removed]
View this email in your browser ([link removed])
BREAKING NEWS ALERT
Moderna said Monday that its two-dose COVID-19 vaccine generates a weaker immune response against a worrisome strain of the disease that first emerged in South Africa, prompting the firm to plan a clinical trial in the United States of a “booster” shot that recipients would receive.

The Cambridge biotech said the South African variant caused a six-fold reduction in neutralizing antibodies generated by the vaccine cleared last month for emergency use by the Food and Drug Administration, based on a new Moderna study. While that’s a dramatic decrease, the company said those antibody levels are still enough to protect people against the South African strain.

Read the full story on BostonGlobe.com ([link removed]) .
Subscribe to BostonGlobe.com ([link removed])
------------------------------------------------------------
We have lots of e-mail newsletters on a variety of topics, including news, politics, business, sports, lifestyle, and more. They're free, and it's easy to subscribe. Here's a complete list. ([link removed])
------------------------------------------------------------
[link removed]
[link removed] [link removed]

============================================================
** Like us ([link removed])
** Follow us ([link removed])
You received this message because you signed up for Breaking News Alerts.

Copyright © 2021 The Boston Globe, All rights reserved.

Our mailing address is:
The Boston Globe
1 Exchange Place Suite 201
Boston, MA 02109-2132
USA

** unsubscribe from this list ([link removed])

** Manage Your Account ([link removed])
| ** Terms of Service ([link removed])
| ** Privacy Policy ([link removed])
| ** Help Center ([link removed])
| ** Advertise (mailto:[email protected]?subject=Advertising+in+BostonGlobe.com)